التفاصيل البيبلوغرافية
| العنوان: |
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. |
| المؤلفون: |
Alkhouri, Naim, LaCerte, Carl, Edwards, Jeffrey, Poordad, Fred, Lawitz, Eric, Lee, Lois, Karan, Sharon, Sawhney, Sangeeta, Erickson, Mary, MacConell, Leigh, Zaru, Luna, Chen, Jianfen, Campagna, Jason |
| المصدر: |
Liver International; Apr2024, Vol. 44 Issue 4, p966-978, 13p |
| مصطلحات موضوعية: |
FARNESOID X receptor, CIRRHOSIS of the liver, FIBROSIS, LIVER histology, PHARMACODYNAMICS, ALANINE aminotransferase |
| مستخلص: |
Background & Aims: Fibrosis stage is a strong predictor of nonalcoholic steatohepatitis (NASH) outcomes. Two blinded studies evaluated the pharmacokinetics, pharmacodynamics and safety of obeticholic acid (OCA) in subjects with staged NASH fibrosis or cirrhosis. Methods: Study 747‐117 randomized 51 subjects with NASH (fibrosis stages F1–F4) to daily placebo, OCA 10 or OCA 25 mg (1:2:2) for 85 days. Study 747‐118 randomized 24 subjects with NASH cirrhosis (F4; Child‐Pugh [CP]‐A) and normal liver control subjects matched for similar body weight to daily OCA 10 or OCA 25 mg (1:1) for 28 days. Individual and combined study data were analysed. Results: No severe or serious adverse events (AEs) or AEs leading to discontinuation or death occurred. Pruritus was the most frequent AE. Plasma OCA exposure (dose‐normalized area under the curve) increased with fibrosis stage but was a relatively poor predictor of hepatic OCA exposure (primary site of action), which remained constant across fibrosis stages F1–F3 and increased 1.8‐fold compared with F1 in subjects with cirrhosis due to NASH. Both cohorts showed robust changes in farnesoid X receptor activation markers with OCA treatment and marked decreases in alanine transaminase, aspartate transaminase and gamma‐glutamyltransferase. Conclusions: Despite higher drug exposures in subjects with NASH cirrhosis, short‐term daily treatment with OCA 10 or 25 mg was generally safe and well tolerated in subjects with NASH fibrosis or NASH CP‐A cirrhosis. Both cohorts experienced improvements in nonhistologic pharmacodynamic markers consistent with previously conducted OCA phase 2 and phase 3 studies in NASH fibrosis. [ABSTRACT FROM AUTHOR] |
|
Copyright of Liver International is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
